Catalyst Pharmaceuticals Secures Flagship Drug Exclusivity Until 2035 Following Legal Settlement
Coral Gables, Thursday, 7 May 2026.
By settling its patent dispute with Hetero Labs, Catalyst Pharmaceuticals secures market exclusivity for its flagship drug until 2035, guaranteeing vital long-term revenue visibility for investors.
Resolving the Patent Overhang
On May 7, 2026, Coral Gables, Florida-based Catalyst Pharmaceuticals (Nasdaq: CPRX) and SERB S.A. entered into a pivotal settlement agreement with Hetero Labs Ltd. and its affiliates, including Annora Pharma Private Limited [1][2]. The agreement resolves ongoing patent litigation concerning Hetero’s Abbreviated New Drug Application (ANDA) to produce a generic version of Firdapse (amifampridine) 10 mg tablets [1]. Under the finalized terms, Hetero Labs is granted a license allowing the company to market its generic alternative in the United States starting in January 2035, provided it secures the requisite approval from the Food and Drug Administration (FDA) [1][3].
A Strategic Legal Victory
This resolution arrives just ahead of a scheduled trial that was set to commence on May 18, 2026, in the U.S. District Court for the District of New Jersey [1]. By averting the trial, Catalyst and Hetero will terminate all associated legal proceedings [1]. Notably, this agreement clears the slate for Catalyst, as the biopharmaceutical company currently has no other pending patent litigation related to Firdapse [3]. To finalize the regulatory process, the companies are required to submit their confidential settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for standard antitrust review [1].
Financial Implications and Market Position
For Catalyst Pharmaceuticals, founded in 2002 and focused on therapies for rare neuromuscular and metabolic diseases, protecting Firdapse is paramount to its commercial strategy [2]. Firdapse is the company’s lead product, indicated for adults suffering from Lambert-Eaton Myasthenic Syndrome (LEMS), while its product Ruzurgi targets pediatric LEMS patients [2]. By securing market exclusivity for another 9 years, the company shores up its long-term revenue visibility [GPT]. Prior to this agreement, Catalyst had successfully navigated and settled similar litigation regarding Firdapse with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited [1].
Continued Growth and Upcoming Earnings
The settlement provides a stable backdrop as the company approaches its first-quarter earnings announcement scheduled for May 11, 2026, following the market close [2]. Analysts project Q1 2026 revenues to reach $148.18 million [2]. If the company sustains this baseline performance across all four quarters, it would generate approximately 592.72 million in annualized revenue [2]. Ahead of the news, Catalyst’s stock closed at $30.52 on May 6, 2026, reflecting a slight daily decrease of $0.34, or -1.10% [2]. Under the leadership of President and Chief Executive Officer Patrick J. McEnany, the firm has consistently expanded its regulatory and commercial footprint within the United States, earning recognition on the Forbes 2025 list of America’s Most Successful Mid-Cap Companies and the 2024 Deloitte Technology Fast 500 [1][2].